Verrica Pharmaceuticals Inc (VRCA) - Net Assets
Based on the latest financial reports, Verrica Pharmaceuticals Inc (VRCA) has net assets worth $24.74 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($47.13 Million) and total liabilities ($22.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check VRCA cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $24.74 Million |
| % of Total Assets | 52.5% |
| Annual Growth Rate | N/A |
| 5-Year Change | -24.11% |
| 10-Year Change | N/A |
| Growth Volatility | 54.54 |
Verrica Pharmaceuticals Inc - Net Assets Trend (2016–2025)
This chart illustrates how Verrica Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore VRCA total assets for the complete picture of this company's asset base.
Annual Net Assets for Verrica Pharmaceuticals Inc (2016–2025)
The table below shows the annual net assets of Verrica Pharmaceuticals Inc from 2016 to 2025. For live valuation and market cap data, see VRCA market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $24.74 Million | +350.94% |
| 2024-12-31 | $-9.86 Million | -149.89% |
| 2023-12-31 | $19.76 Million | -50.63% |
| 2022-12-31 | $40.03 Million | +22.78% |
| 2021-12-31 | $32.60 Million | -1.16% |
| 2020-12-31 | $32.99 Million | -49.26% |
| 2019-12-31 | $65.02 Million | -27.30% |
| 2018-12-31 | $89.43 Million | +1370.12% |
| 2017-12-31 | $-7.04 Million | -164.30% |
| 2016-12-31 | $-2.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Verrica Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 32223700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.01% |
| Other Components | $349.65 Million | 1413.14% |
| Total Equity | $24.74 Million | 100.00% |
Verrica Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Verrica Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nava Nakorn Public Company Limited
BK:NNCL
|
$100.23 Million |
|
Taiwan Line Tek Electronic Co Ltd
TW:2462
|
$100.24 Million |
|
Balyo SA
PA:BALYO
|
$100.26 Million |
|
Daldrup & Söhne Aktiengesellschaft
F:4DS
|
$100.27 Million |
|
Sona Topas Tourism Industry
JK:SONA
|
$100.14 Million |
|
Aztek Teknoloji Urunleri Ticaret A.S.
IS:AZTEK
|
$100.12 Million |
|
T.A.C. Consumer Public Company Limited
BK:TACC
|
$100.05 Million |
|
Yong Pyong Resort Corp
KO:070960
|
$100.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Verrica Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -9,860,000 to 24,743,000, a change of 34,603,000.
- Net loss of 17,886,000 reduced equity.
- New share issuances of 50,067,000 increased equity.
- Other factors increased equity by 2,422,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-17.89 Million | -72.29% |
| Share Issuances | $50.07 Million | +202.35% |
| Other Changes | $2.42 Million | +9.79% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Verrica Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.70x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-1.04 | $6.27 | x |
| 2017-12-31 | $-2.74 | $6.27 | x |
| 2018-12-31 | $60.99 | $6.27 | x |
| 2019-12-31 | $26.11 | $6.27 | x |
| 2020-12-31 | $13.20 | $6.27 | x |
| 2021-12-31 | $12.06 | $6.27 | x |
| 2022-12-31 | $11.72 | $6.27 | x |
| 2023-12-31 | $4.36 | $6.27 | x |
| 2024-12-31 | $-1.90 | $6.27 | x |
| 2025-12-31 | $2.32 | $6.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Verrica Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -72.29%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -50.27%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 1.90x
- Recent ROE (-72.29%) is above the historical average (-78.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.65 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.75 Million |
| 2018 | -23.09% | 0.00% | 0.00x | 1.03x | $-29.59 Million |
| 2019 | -42.99% | 0.00% | 0.00x | 1.05x | $-34.45 Million |
| 2020 | -137.93% | -379.14% | 0.16x | 2.25x | $-48.80 Million |
| 2021 | -107.59% | -292.33% | 0.15x | 2.46x | $-38.34 Million |
| 2022 | -61.17% | -271.11% | 0.20x | 1.12x | $-28.49 Million |
| 2023 | -338.99% | -1307.47% | 0.06x | 4.13x | $-68.97 Million |
| 2024 | 0.00% | -1012.15% | 0.14x | 0.00x | $-75.59 Million |
| 2025 | -72.29% | -50.27% | 0.75x | 1.90x | $-20.36 Million |
Industry Comparison
This section compares Verrica Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Verrica Pharmaceuticals Inc (VRCA) | $24.74 Million | 0.00% | 0.90x | $100.15 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the tr… Read more